Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05521919 · ClinicalTrials.gov registry record · NA

Acute Plasma Abeta Responses to Stress

A NA study, sponsored by University of Southern California.

Completed
Registry status
NA
Development phase
38
Enrollment target

NCT05521919: Completed NA study, sponsored by University of Southern California.

NCT05521919 is a NA study that has completed, run by University of Southern California. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05521919, a NA study, has completed, sponsored by University of Southern California.

COMPLETED
Registry status
NA
Development phase
38 participants
Enrollment target

Study Summary

Research has shown that activation of the sympathetic nervous system for extended periods or during certain times in life can increase the risk for Alzheimer's disease. Some research in animal models show that acute activation of the sympathetic nervous system through stress exposure can increase certain Alzheimer's disease-related biomarkers, such as amyloid-beta, within hours of exposure. However, how acute sympathetic nervous system activation via stress exposure affects amyloid-beta levels in humans has yet to be examined. In this study, the investigators will examine whether brief increases in sympathetic activation result in immediate changes in plasma amyloid-beta levels in the five hours after exposure.

Primary Outcome

Changes in levels of amyloid-beta-40 in blood from before to after acute intervention (stress/no-stress).

Interventions

  • BEHAVIORAL Sympathetic Nervous System Activation
  • BEHAVIORAL No-stress

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2023-12-05
Est. Completion 2024-12-10
Phase NA
University of Southern California

617 total trials

What the finished NCT05521919 record still lists

NCT05521919 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 2 interventions - of which Sympathetic Nervous System Activation is the first listed.

NCT05521919 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05521919 about?

NCT05521919 is a clinical study titled "Acute Plasma Abeta Responses to Stress". Research has shown that activation of the sympathetic nervous system for extended periods or during certain times in life can increase the risk for Alzheimer's disease. Some research in animal models show that acute activation of the sympathetic nervous system through stress exposure can increase ce...

What is the current status of trial NCT05521919?

This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2023-12-05. Estimated completion is 2024-12-10.

What interventions are being tested in trial NCT05521919?

The interventions under investigation include: Sympathetic Nervous System Activation (BEHAVIORAL), No-stress (BEHAVIORAL).

Who is sponsoring clinical trial NCT05521919?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05521919's enrollment target sits among peer trials

38 1538th of 2000 higher than 461 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01684904 · 38 participants · NA

    Proton Therapy for Esophageal Cancer

  • NCT03310879 · 38 participants · Phase 2

    Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

  • NCT03896269 · 38 participants · Phase 1

    CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  • NCT04085315 · 38 participants · Phase 1

    Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05521919, the US trial registry maintained by the National Library of Medicine. NCT05521919 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.